Acadia Pharmaceuticals will disclose first quarter 2026 financial results after market close today, followed by a management-hosted conference call at 4:30 p.m. ET.

Samsung Bioepis and ATLATL have signed a Memorandum of Understanding to drive early-stage biotech innovation across the Asia-Pacific region through enhanced collaboration.

India's Sun Pharmaceuticals is acquiring Organon & Co. for $11.75 billion to enhance its women's health portfolio, biosimilars, and global reach from its Mumbai base.[2]

The U.S. government has enacted measures to reduce reliance on imported pharmaceuticals and active pharmaceutical ingredients, citing threats to national security and supply chain vulnerabilities.

Axsome Therapeutics has obtained US FDA approval for Auvelity to treat agitation in Alzheimer's disease, marking a significant advancement in pharmaceutical treatments for neurodegenerative disorders.

Ridgetech, a leading Chinese pharmaceutical wholesaler, announced its 2026 dual-engine growth strategy focusing on supply chain integration and B2B platform expansion to enhance efficiency in the pharma and healthcare sector.

Gilead Sciences has completed its acquisition of Arcellx in a deal valued at approximately $7.8 billion. Anito-cel is a BCMA-directed CAR T-cell therapy that uses a D-domain binder. This design aims to improve CAR expression while reducing unwanted immune activity. The therapy is being developed

Bausch Health is set to report Q1 2026 earnings after market close today, April 29, 2026, with analysts forecasting a 37% EPS increase driven by key product performance amid patent pressures.

Hong Kong government has inked agreements with 22 technology companies, including Pfizer, to enhance innovation in life and health technologies within the region.

Hong Kong government signed agreements with 22 companies, including pharmaceutical giant Pfizer, to establish or expand operations in life and health technology, attracting significant investments and jobs.